CSI Market
Sign In | Register

Acer Therapeutics Inc (ACER) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ACER Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Acer Therapeutics Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
9 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-39.10
Depreciation & amortization0.04
Amortization of Other Assets0.41
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Increase (Decrease) in Inventories-5.20
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.14
Share-based Compensation0.78
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt8.54
Stock Payable For Acquired Research And Development-
Stock Issued For Acquired Research And Development-
Stock Issued For Debt In Excess Of Principal-
Noncash Interest Expense-
Fair Value Of Shares Issued For Commitment Fee-
Non Cash Interest Expenses-
Non Cash Changes In Fair Value Of Debt6.74
Debt Issuance Costs Recognized As Expense0.17
Increase Decrease In Collaboration Receivable-
Increase Decrease In Deferred Collaboration Funding-3.87
Increase Decrease In Deferred Collaboration Funding-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable3.20
Increase (Decrease) in Accrued Liabilities1.86
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.43
Other Working Capital0.01
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-3.05
Discontinued operations0.00
Net Cash flow from Operating Activities-28.90
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net1.00
Other borrowing transactions-0.17
Long-term debt - borrowings-0.60
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net20.41
Proceeds From The Exercise Of Stock Options And Warrants-
Proceeds From Exercise Of Stock Options And Warrants-
Proceeds From Stock Options And Warrants Exercised-
Cash Paid For Fractional Shares-
Stock Repurchase Reverse Stock Split Value Fractional Shares-
Deferred Financing Cost-
Proceeds From Issuance Of Common Stock Net Of Issuance Costs-
Proceeds From Paycheck Protection Program Loan-
Proceeds From Bridge Loan Net Of Warrant Allocation And Lender Fees-
Proceeds From Original Term Loan Net Of Warrant Allocation And Lender Fees-
Proceeds From Second Term Loan Net Of Warrant Allocation And Lender Fees6.53
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities27.17
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-28.91
Total Cash Flow-1.73
4 historic quarters locked

Sign in to unlock the full Acer Therapeutics Inc cash flow history.

Sign In Create Free Account

About Acer Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-065159

Figures are derived from filed reports and may be restated. Historical data is subject to revision.